Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2001;89:977-982
Published online before print November 1, 2001, doi: 10.1161/hh2301.100982
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
89/11/977    most recent
hh2301.100982v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neri Serneri, G. G.
Right arrow Articles by Galanti, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neri Serneri, G. G.
Right arrow Articles by Galanti, G.
Related Collections
Right arrow Contractile function
Right arrow Other myocardial biology
Right arrow Hypertrophy
Right arrow Clinical Studies
(Circulation Research. 2001;89:977.)
© 2001 American Heart Association, Inc.


Clinical Research

Increased Cardiac Sympathetic Activity and Insulin-Like Growth Factor-I Formation Are Associated With Physiological Hypertrophy in Athletes

Gian Gastone Neri Serneri, Maria Boddi, Pietro Amedeo Modesti, Ilaria Cecioni, Mirella Coppo, Luigi Padeletti, Antonio Michelucci, Andrea Colella, Giorgio Galanti

From the Clinica Medica Generale e Cardiologia, University of Florence, Italy.

Correspondence to Prof Gian Gastone Neri Serneri, MD, Clinica Medica Generale e Cardiologia, University of Florence, Viale Morgagni 85, 50134 Florence, Italy. E-mail gg.neriserneri{at}dfc.unifi.it

Physiological hypertrophy represents the adaptive changes of the heart required for supporting the increased hemodynamic load in regularly trained healthy subjects. Mechanisms responsible for the athlete’s hypertrophy still remain unknown. In 15 trained competitive soccer players and in 15 healthy men not engaged in sporting activities (sedentary control subjects) of equivalent age, we investigated the relationship among cardiac growth factor formation, cardiac sympathetic activity, and left ventricular morphology and function. Cardiac formation of insulin-like growth factor (IGF)-I, endothelin (ET)-1, big ET-1, and angiotensin (Ang) II was investigated at rest by measuring artery-coronary sinus concentration gradients. Cardiac sympathetic activity was studied by [3H]norepinephrine (NE) kinetics. Cardiac IGF-I, but not ET-1, big ET-1, and Ang II, formation was higher in athletes than in control subjects (P<0.01). NE levels in arterial and peripheral venous blood did not differ between groups. In contrast, coronary sinus NE concentration was higher in athletes than in control subjects (P<0.01). Cardiac, but not total systemic, NE spillover was also increased in athletes (P<0.01), whereas cardiac [3H]NE reuptake and clearance were not different. Echocardiographic modifications indicated a volume overload-induced hypertrophy associated with increased myocardial contractility. Multivariate stepwise analysis selected left ventricular mass index as the most predictive independent variable for cardiac IGF-I formation and velocity of circumferential fiber shortening for cardiac NE spillover. In conclusion, increased cardiac IGF-I formation and enhanced sympathetic activity selectively confined to the heart appear to be responsible for the physiological hypertrophy in athletes performing predominantly isotonic exercise.


Key Words: insulin-like growth factor-I • norepinephrine • sympathetic nervous system • exercise • hypertrophy, left ventricular




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. R. McMullen, F. Amirahmadi, E. A. Woodcock, M. Schinke-Braun, R. D. Bouwman, K. A. Hewitt, J. P. Mollica, L. Zhang, Y. Zhang, T. Shioi, et al.
Protective effects of exercise and phosphoinositide 3-kinase(p110{alpha}) signaling in dilated and hypertrophic cardiomyopathy
PNAS, January 9, 2007; 104(2): 612 - 617.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Mancia, M. Bombelli, G. Corrao, R. Facchetti, F. Madotto, C. Giannattasio, F. Q. Trevano, G. Grassi, A. Zanchetti, and R. Sega
Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study: Daily Life Blood Pressure, Cardiac Damage, and Prognosis
Hypertension, January 1, 2007; 49(1): 40 - 47.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
I. Shiojima and K. Walsh
Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway
Genes & Dev., December 15, 2006; 20(24): 3347 - 3365.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. DeBosch, N. Sambandam, C. Weinheimer, M. Courtois, and A. J. Muslin
Akt2 Regulates Cardiac Metabolism and Cardiomyocyte Survival
J. Biol. Chem., October 27, 2006; 281(43): 32841 - 32851.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. Abe, T. Matsunaga, K. Kameda, H. Tomita, T. Fujiwara, H. Ishizaka, H. Hanada, K. Fukui, I. Fukuda, T. Osanai, et al.
Increased Level of Pericardial Insulin-Like Growth Factor-1 in Patients With Left Ventricular Dysfunction and Advanced Heart Failure
J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1387 - 1395.
[Abstract] [Full Text] [PDF]


Home page
Eur J EchocardiogrHome page
R. M. Lang, M. Bierig, R. B. Devereux, F. A. Flachskampf, E. Foster, P. A. Pellikka, M. H. Picard, M. J. Roman, J. Seward, J. Shanewise, et al.
Recommendations for chamber quantification
Eur J Echocardiogr, March 1, 2006; 7(2): 79 - 108.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. J. R. Barton, L. E. Felkin, E. J. Birks, M. E. Cullen, N. R. Banner, S. Grindle, J. L. Hall, L. W. Miller, and M. H. Yacoub
Myocardial Insulin-Like Growth Factor-I Gene Expression During Recovery From Heart Failure After Combined Left Ventricular Assist Device and Clenbuterol Therapy
Circulation, August 30, 2005; 112(9_suppl): I-46 - I-50.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Konhilas, U. Widegren, D. L. Allen, A. C. Paul, A. Cleary, and L. A. Leinwand
Loaded wheel running and muscle adaptation in the mouse
Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H455 - H465.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Merkus, A. K. Brzezinska, C. Zhang, S. Saito, and W. M. Chilian
Cardiac myocytes control release of endothelin-1 in coronary vasculature
Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2088 - H2092.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Konhilas, A. H. Maass, S. W. Luckey, B. L. Stauffer, E. N. Olson, and L. A. Leinwand
Sex modifies exercise and cardiac adaptation in mice
Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2768 - H2776.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M. C. Sherwood, A. L. Dorfman, S. Longnus, M. Pende, K. A. Martin, J. Blenis, et al.
Deletion of Ribosomal S6 Kinases Does Not Attenuate Pathological, Physiological, or Insulin-Like Growth Factor 1 Receptor-Phosphoinositide 3-Kinase-Induced Cardiac Hypertrophy
Mol. Cell. Biol., July 15, 2004; 24(14): 6231 - 6240.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. R. McMullen, T. Shioi, W.-Y. Huang, L. Zhang, O. Tarnavski, E. Bisping, M. Schinke, S. Kong, M. C. Sherwood, J. Brown, et al.
The Insulin-like Growth Factor 1 Receptor Induces Physiological Heart Growth via the Phosphoinositide 3-Kinase(p110{alpha}) Pathway
J. Biol. Chem., February 6, 2004; 279(6): 4782 - 4793.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B. J. Wilkins, Y.-S. Dai, O. F. Bueno, S. A. Parsons, J. Xu, D. M. Plank, F. Jones, T. R. Kimball, and J. D. Molkentin
Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy
Circ. Res., January 9, 2004; 94(1): 110 - 118.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. A. Modesti, S. Vanni, I. Bertolozzi, I. Cecioni, C. Lumachi, A. M. Perna, M. Boddi, and G. F. Gensini
Different Growth Factor Activation in the Right and Left Ventricles in Experimental Volume Overload
Hypertension, January 1, 2004; 43(1): 101 - 108.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M. C. Sherwood, P. M. Kang, and S. Izumo
Phosphoinositide 3-kinase(p110{alpha}) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy
PNAS, October 14, 2003; 100(21): 12355 - 12360.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. P. Schlaich, D. M. Kaye, E. Lambert, M. Sommerville, F. Socratous, and M. D. Esler
Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy
Circulation, August 5, 2003; 108(5): 560 - 565.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. G.F Bronzwaer, C. Zeitz, C. A Visser, and W. J Paulus
Endomyocardial nitric oxide synthase and the hemodynamic phenotypes of human dilated cardiomyopathy and of athlete's heart
Cardiovasc Res, August 1, 2002; 55(2): 270 - 278.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Zoccali, F. Mallamaci, G. Tripepi, S. Parlongo, S. Cutrupi, F. A. Benedetto, A. Cataliotti, and L. S. Malatino
Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease
Hypertension, July 1, 2002; 40(1): 41 - 46.
[Abstract] [Full Text] [PDF]